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Reshaping AHCs’ Role
in Biomedical Research
While marking dramatic increases in managed care,
training of primary care practitioners, and biotechnology advances, the 1990s chronicled a downturn in
academic health center (AHC) fortunes. The increases
had a direct impact upon AHCs’ historic missions:
delivery of health services, provision of medical education, and conduct of biomedical (especially clinical)
research. Toward the end of the decade, changes in
federal payment policy began to have an adverse impact
on the bottom lines of teaching hospitals, further
affecting AHC prospects. These changes included a
freeze on the rate of increase in payment for Medicare
services and cuts in subsidies for the care of lowincome persons and for the graduate education of
medical residents.
With managed care organizations diverting services
to less costly health care providers, affected AHCs
experienced strains in their service bases. And with
pharmaceutical conglomerates and biotechnology firms
rapidly outpacing them in the conduct of biomedical
research and with nonacademic entities emerging to
organize clinical trials and other research functions,
affected AHCs saw their research bases threatened as
well. Despite these problems, however, those ready to
dismiss AHCs as unviable in a reconfigured health
marketplace received a strong warning from the scientific community. As the educators of biomedical
researchers—those with Ph.D.s as well as those with
M.D.s—AHCs cannot easily be counted out. Moreover,
the teaching hospitals of some AHCs serve as safety-net
providers, with interns and residents as relatively lowpaid staff. The commingling of service delivery, medical education, and medical research is a powerful mix,
as legislators on Capitol Hill and in state capitols have
heard time and time again.
AHCs partnered with the National Institutes of
Health (NIH) and other government agencies, as well as
private pharmaceutical, biotechnology, and medical
device companies, to propel the United States to leadership in biomedical research in the second half of the
20th century. As the century ends, they face an uncertain
future. The titles of various reports on their plight tell
the story: “The Changing Landscape for Clinical Research,”1 “The Impact of Managed Care on Clinical
Research: A Preliminary Investigation,”2 “Managed
Care Squeezes Research Funds and Charity Health Aid,

Studies Find,”3 and From Bench to Bedside: Preserving
the Research Mission of Academic Health Centers.4 But
AHCs are ending the decade of the ‘90s on an up note.
Enactment of the Medicare, Medicaid, and SCHIP
(State Children’s Health Insurance Program) Balanced
Budget Refinement Act of 1999 will restore some
service and subsidy cuts made by the Balanced Budget
Act of 1997 (BBA), and new efforts to address and
reshape AHCs’ role in clinical research and health
outcomes investigation are under way.
This Forum session—the first in a series of meetings
on the public stake in biomedical research—will explore
AHCs’ changing role. It will look at AHCs as they have
reconfigured to meet health marketplace and other
pressures, as well as their relationships to the continuum
of biomedical inquiry. The session will also examine the
problems confronting AHCs, public and private incentives and pressures they face, and initiatives they have
undertaken or that have been undertaken in their behalf.

BACKGROUND
In a rapidly changing health marketplace, characterized by the merger or takeover of existing provider and
insurer organizations to form new entities and by the
emergence of hybrid organizations to address new or
altered functions, there is no absolute definition of an
AHC, sometimes called an academic medical center
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(AMC). The Association of Academic Health Centers
defines an AHC as “an entity that has an allopathic or
osteopathic medical school, one or more other health
professional schools or programs (such as nursing,
public health, or pharmacy), and one or more teaching
hospitals.”5 A 1998 Association of American Medical
Colleges (AAMC) document on “biomedical and health
sciences research” notes that the “biomedical research
system nurtured by [federal grants-in-aid and patient
care revenues] has grown to include 125 allopathic
medical schools and more than 400 teaching hospitals
as part of 1,700 institutions receiving NIH support.”6
According to Gerard Anderson, Ph.D., and two
colleagues, the first institution to integrate patient care,
clinical education, and research was Johns Hopkins
University, which opened its medical school in 1893.
The 1910 Flexner Report strongly supported this model,
which Columbia University and Presbyterian Hospital
adopted that same year, thereby becoming the first
AHC formed as a result of a merger. As Anderson and
his co-authors point out:
Most of the growth of AHCs occurred in the period
following World War II, when policymakers in
Washington decided to expand the number and size of
medical schools, invest heavily in biomedical research, adopt a generous payment system for services
provided by hospitals and physicians, and adopt other
regulatory and financing initiatives that have encouraged the expansion of AHCs.7

The co-authors also indicate that AHCs traditionally
have these commonalties: (a) faculty heavily involved
in “biomedical and clinical research,” (b) commitment
to patient services that are highly specialized, and (c)
dedication to pre- and postdoctoral teaching, carried on
by a large faculty who spend only a small amount of
time in teaching activities.8

recommended that the following be adopted: “Clinical
research is a component of medical and health research
intended to produce knowledge valuable for understanding human disease, preventing and treating illness,
and promoting health.” In their view, it encompasses
disease mechanisms; translational research; clinical
knowledge, detection, diagnosis, and natural history of
disease; therapeutic interventions, including clinical
trials; prevention and health promotion; behavioral
research; health sciences research; epidemiology; and
community-based and managed care-based trials.9
Hence, it tends to encompass nearly all the research
activities in which AHCs are engaged.

THE PROBLEMS
As indicated in the background paper that introduced this series of meetings,10 the patient care, medical
education, and research dollars that have contributed to
AHCs’ strength in the health arena have also made
them vulnerable. More costly because of their joint
missions, they have been less attractive to managed care
plans seeking lower costs per member. For example,
according to data from HCIA, a Baltimore-based health
information company, the median expense per adjusted
admission for a major teaching hospital was $9,833 in
1998, while the median revenue per adjusted admission
was $9,935. In contrast, the medians for all hospitals
that year were $5,065 (expense per adjusted admission)
and $5,181 (revenue per adjusted admission).

There also are differences in terminology and
definitions of biomedical research. Some see it as a
continuum, beginning with basic research or “bench”
science, continuing with translational research (to
“translate” basic science into new methods of diagnosis
and treatment), moving to clinical investigation, and
ending with outcomes studies. Others prefer to forego
the term “biomedical” and use individual (rather than
blanket) terms, such as basic, translational, clinical, and
health sciences research.

Moreover, payers and risk organizations have been
less willing to subsidize medical education than were
traditional insurers under fee-for-service arrangements. Also, the BBA started ratcheting down federal
indirect medical education payments under Medicare,
and state Medicaid programs have been uneven in
their recognition of medical education costs. Moreover, health plans generally refused to pay the costs of
care for their members in clinical trials, thereby having
a chilling effect on patients’ participation in them.11
“In sum,” as the authors of “The Changing Landscape
for Clinical Research” contend, “clinical research in
AMCs became extraordinarily susceptible to modifications of federal policies of sponsored research support
and changes in the organization, financing, and
delivery of medical care.”12

Research participants from various aspects of the
field who were convened by the AAMC, the American
Medical Association (AMA), and Wake Forest University in 1998 viewed the lack of an agreed-upon definition of clinical research as a major problem. They

As the health marketplace placed greater value on
delivery of services in ambulatory rather than inpatient
settings, on financing of care under capitated or discounted arrangements rather than fee for service, and
upon primary rather than specialty care, AHCs lost
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ground. Their common elements—high faculty-topatient ratios because of clinician-scholars’ involvement
in teaching and research, high specialty-to-generalist
ratios, and high faculty-to-student ratios—turned out to
be liabilities in a reconfigured environment. Added to
this were the higher capital costs needed to maintain
and perpetuate the academic medicine enterprise,
although some of the major medical schools and
teaching hospitals have endowments and capital gifts to
help underwrite the costs.
Perhaps because of the marketplace changes (not
only the decreased attraction of biomedical investigation but also the increased attraction of other fields of
endeavor in the health field), the numbers of personnel
entering the field, particularly clinical investigators and
especially M.D.-trained researchers, are decreasing.
Warnings first sounded in the late 1980s, gained
legitimacy partly as a result of a 1991 Institute of
Medicine (IOM) study (Careers in Clinical Research:
Obstacles and Opportunities), and achieved even more
credence when several NIH panels stressed the importance of recruiting and retaining fellows, new investigators, and seasoned researchers. In view of the pressure
upon AHCs to educate more primary care practitioners
and to put more emphasis upon training in ambulatory
settings, some institutions are putting clinician-educators and clinician-investigators on separate tracks. “Just
as researchers excel at the discovery of new knowledge
but have little time for teaching and clinical care,
clinician-educators excel at teaching and clinical care
but have little time to conduct research.”13 This approach requires AHCs to provide different advancement
criteria for faculty in the two tracks, without favoring or
penalizing either. Because the AHC is crucial to the
recruitment, nurturing, and production of biomedical
researchers—whether M.D. or Ph.D. or both—it is the
focus of most efforts to address the problem of the socalled disappearing investigator.

PUBLIC AND PRIVATE INCENTIVES
AND PRESSURES
Although the NIH, part of the Department of Health
and Human Services (DHHS), is mentioned most often as
AHCs’ partner in biomedical research, other federal
agencies are important as well. At DHHS, these include
the Agency for Healthcare Research and Quality
(AHRQ), which conducts health services research on
access, cost, and quality issues; the Centers for Disease
Control and Prevention (CDC), which work on disease
and injury prevention and environmental health; the Food

and Drug Administration, which is responsible for food,
cosmetic, drug, medical device, and radiation-emitting
product safety; and the Health Care Financing Administration, which administers and oversees delivery of
Medicare, Medicaid, and Child Health Insurance Program
services. Another key partner is the Department of
Veterans Affairs (VA), which is involved in research on
fundamental biological processes, clinical trials, health
services research, and disability and functional concerns.
AHCs are most closely associated with the NIH—
conducting more than half of the research funded by its
various institutes—and with the VA, which also is
involved in patient care, medical education, and research. Their ties with the other agencies are growing,
as they focus more on health services research, disease
and injury prevention, and primary care, the purview of
another DHHS agency, the Health Resources and
Services Administration. But NIH remains the giant; for
instance, fiscal year 2000 appropriations for AHRQ
($205 million) and the CDC ($2.9 billion) pale beside
the NIH’s $17.9 billion.
Of the $42 billion of research and development
funding in the United States in 1997, AHCs received
$12 billion, or 28 percent, according to the authors of
From Bench to Bedside. The majority of funds to AHCs
came from the federal government, primarily from the
NIH. Federal research funds tended to be concentrated
in a few institutions, “a pattern that can be illustrated
with data from the NIH. In 1996, 5 percent of AHCs
received 25 percent of all NIH funds, and 15 percent of
AHCs received 50 percent of all NIH funds.”14 The top
ten were the following:15
AHC

Percentage

Eight affiliated institutions
grouped as one:
Harvard University
Massachusetts General Hospital
Brigham and Women’s Hospital
Dana-Farber Cancer Institute
Children’s Hospital (Boston)
Beth Israel Hospital (Boston)
New England Deaconess Hospital
Massachusetts Eye and Ear Infirmary

7.35

Johns Hopkins University
and its facilities

4.06

University of Washington

4.00

University of Pennsylvania
and its Children’s and
Graduate Hospitals

2.95
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University of California
San Francisco and
San Francisco General Hospital
Medical Center

2.93

Washington University
with Barnes Jewish Hospital

2.53

University of Michigan

2.47

University of California
Los Angeles with its affiliated
institutions

2.44

Yale University

2.40

Stanford University

2.11

from 34 percent to 43 percent,” while the NIH’s share
“has decreased from about 35 percent . . . to about 29
percent today.”16

In some ways, the federal agencies cut across the
continuum of biomedical research—from basic discoveries, to the translation of discoveries from “bench to
bedside,” to clinical practice, and to outcomes and
quality initiatives. Unlike health agencies in most other
countries, where research is centralized, the work
conducted under their aegis is largely carried out in the
private sector, under grants and contracts, subject to the
dictates of the health marketplace. While some think
this encourages innovation and creativity, others fear
that it may result in misalignment of priorities and of
proprietary claims to so-called public knowledge. The
marketplace is highly politicized, with legislators’
responses to disease group advocates driving the
authorization and appropriation of funds and the
support of disease-directed research efforts. The NIH,
however, has done significant work comparing the
allocation of public dollars according to the burden of
illness and is continually under pressure to re-examine
its priorities. Nonetheless, by all accounts, the federalAHC partnership that has developed in this political,
pluralistic system has served the nation well, leading to
concerns that significant changes—in response to new
marketplace incentives—may skew research priorities,
projects, and applications.
In the support and conduct of biomedical research,
however, the private sector has surpassed the public
sector. It has done so not only in the research carried on
by pharmaceutical firms, biotechnology companies, and
medical device manufacturers but also in the clinical
and other investigation organized by some health
systems and plans, contract research organizations
(CROs) that arrange and monitor clinical trials, and
physician-based research networks that implement
research protocols and handle data collection. As
indicated by the NHPF background paper, since the
mid-1980s, the “industry’s share of total health research
and development (R&D) expenditures has increased

AHCs, which include both public (usually stateoperated) and private academic institutions, partner
with private enterprises as well as government agencies.
For example, “since 1965, the Pharmaceutical Research
and Manufacturers of America (PhRMA) Foundation
has supported nearly 2,400 young researchers with
almost $44 million from contributions from PhRMA
members.”17 These range from undergraduate through
post-doctoral awards and faculty awards and grants in
academic research settings. Moreover, many AHCs,
worried about declines in research support and about
competitive threats from CROs, “are aggressively
marketing their services to industrial research customers,” according to From Bench to Bedside. The report
cites several risks:
For example, faculty members receiving industry
support are more likely than others to choose research
topics according to the potential for commercial
application and more likely to experience delays in
publishing. Life science companies that sponsor
research in academic institutions typically require
investigators to keep their results secret six months or
more to protect their commercial value. Faculty with
industrial support are more likely to withhold results
from colleagues and to report that trade secrets have
resulted from their work. These findings suggest that,
unless carefully managed, the pursuit of industrial
research support may have adverse consequences for
academic norms in AHCs.18

The report also notes that CROs have grown from
approximately 200 in 1974 to about 1,300 in the late
1990s and indicates “that 57 percent of all clinical
trials were performed by investigators not affiliated
with AHCs.”19
Anderson and his co-authors delineated four roles
for AHCs in medical innovation. These roles cut across
both publicly and privately sponsored research. The
first is “the development of new drugs, devices, diagnostic techniques, and therapeutic procedures.” The
second is adoption, being “the first institutions to
acquire and use new technologies, instruments, and
drugs.” The third is evaluation “of new technologies
that have not yet diffused into medical practice” as well
as “of technologies that already are used routinely but
have not been carefully evaluated in all of the clinical
settings in which they are used.” The fourth is advisory,
identifying “the clinical need for certain drugs, surgical
instruments, and diagnostic services” and providing
“valuable scientific and clinical expertise during their
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early and later stages of development.” Moreover, the
co-authors underline AHCs’ contribution to education
of innovators: “ranging from undergraduate medical
education all the way through graduate medical education, doctorate training in research, and continuing
education for practitioners—and the impact of that
education on the health care system.”20

SOME SOLUTIONS
In looking at problems that AHCs face and at
approaches for addressing them, it is important to note
that there is a great deal of variation among AHCs.
While nearly all are nonprofit, some are public, connected to state universities or other governmentally
owned entities. Others are private—in some cases, parts
of integrated delivery systems; in other cases, parts of
religious organizations; and, in still others, of community or other sponsors. While it seems to be common
wisdom that AHCs in general are adversely affected by
competitive marketplace changes and by public policy
actions, their responses to market reconfiguration and
delivery and payment provisions vary a great deal. How
well they are faring depends upon various factors, such
as where they are located and what kinds of capital
sources and revenue flows they have (and how secure
the sources and flows are).
While the financial data cover only the first half of the
1990s (from 1989 through 1995), the AAMC’s The
Financing of Medical Schools distinguishes the revenues
of public and private medical schools. It breaks down the
revenues of four subsets of schools (public researchintensive, private research-intensive, community-based
schools, and private freestanding schools) as well as of
osteopathic schools. The contrasts are striking: in 1995,
the median total revenues of private research-intensive
schools were $480.2 million, while the median total
revenues of community-based schools were $57.6 million
(and for osteopathic schools, even lower—$24.4 million).
In terms of revenue sources—faculty practice plans,
hospital revenues, endowments and gifts, federal research, state and local appropriations, tuition and fees,
and other—the proportions of the sources for each subset
tended to vary greatly. For example, federal research
contributed 30 percent of the median total revenues of the
private research-intensive schools and only 6 percent of
the median total revenues of the community-based
schools (and 5 percent of the osteopathic schools).21
The task force reached its conclusions prior to
passage of the BBA, which enacted delivery and
financing changes for fiscal year (FY) 1998 through FY

2002 that AHCs, for the most part, have viewed as
inimical. These changes affected the annual rates of
increase under the Medicare prospective payment
system (PPS) for teaching and other inpatient hospitals,
the disproportionate-share hospital (DSH) adjustment
under Medicare for hospitals with heavy caseloads of
low-income patients, the indirect medical education
(IME) adjustment for each diagnosis-related group
under PPS for teaching hospitals, and formula payments
for capital expenses under Medicare for teaching and
other hospitals. They also mandated payment for
hospital outpatient services, inclusion of post-acute
services under PPS, and incentives for Medicare
beneficiaries to enroll in Medicare+Choice managed
care plans under capitated or other at-risk financial
arrangements.
On the AHC medical school side, the task force
recommendations focused on the three AHC missions.
Relative to patient care, they centered on “improving
the competitiveness of the clinical enterprise,” such as
by emphasizing generalist medicine, integrated
multidisciplinary group practice, and clinical information systems. Relative to medical education, they urged
collaboration among and merger of medical school
programs; “increased use of small-group, interactive
teaching in the preclinical curriculum” and greater use
of “advanced information technology”; as well as
“movement of clinical education from inpatient hospital
settings to ambulatory and community settings, including managed care practice settings.” Relative to research, they supported changes in financing, for the
most part, whether cost-sharing by various public and
private sponsors, federal research grants, or initiation of
new support grant programs.22
On the AHC teaching hospital side, the industry
lobbied hard to soften the BBA changes and was successful in moderating some. The Medicare, Medicaid, and
SCHIP Balanced Budget Refinement Act of 1999 decreased the reduction in the DSH adjustment and slowed
the implementation of cuts in IME. It also eased the
application of the outpatient PPS and made some changes
in implementation of PPS for post-acute services.23
As AHCs addressed patient care and health professions education, there was a search for leadership relative
to the third mission, research. While the scientific and
policy literature resounded with warnings of doom, the
NIH convened panels to study recruitment and retention
of physician investigators in clinical research careers and
other issues, the IOM examined priority-setting at the
NIH, and the Commonwealth Fund undertook its work
on AHC missions. The AAMC, AMA, and Wake Forest
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School of Medicine undertook a Clinical Research
Summit, culminating in the projected establishment, early
in 2000, of a Clinical Research Roundtable at the IOM.
Among other activities centered on clinical research, the
roundtable will promote dialogue among the scientific
community and the general public, establish mechanisms
to track financial and other support, create a process to
monitor and promote workforce career development
across the health professions, and develop databases for
patient- and population-based health research. It will also
strengthen the linkages between basic science discoveries
and their application to improved patient care, ensure
AHCs’ ability to conduct research and training, broaden
the participation of the health professions, and work on
strategies for disseminating new clinical research findings and evaluating outcomes of new procedures and
treatments.
A vast array of organizations are involved in helping
determine what shape biomedical research will take in
the next decade and what contributions AHCs will
make. In addition to AHCs themselves and the organizations that represent them, charitable foundations,
coalitions of medical and scientific societies, diseasecentered interest groups, voluntary health organizations,
and academic and research organizations are involved
in the endeavor. At this time, there seem to be more
questions than answers, questions that NHPF plans to
explore at this Forum session.












KEY QUESTIONS
Following are the key questions that will provide a
format for the Forum meeting:







In what ways are AHCs alike and in what ways are
they different relative to their fulfillment of the
patient care, health professions education, and
biomedical research missions? Are the three missions crucial to the identification of AHCs?
What is the breadth and scope of biomedical research (or of the continuum of basic, translational,
clinical, and outcomes research)? What roles have
AHCs played traditionally? How are they changing?
What is the nature of AHC relationships with
different federal agencies? What roles do the agencies play in shaping and nurturing the public stake in
biomedical research?
What impact has reconfiguration of the health
marketplace had on AHCs as a group? On different
types of AHCs? How do they remain vital? What
form will (should) they take?






What effects has the BBA had on teaching hospitals? How accurate are the projections of effects in
future years? Will provisions of the Medicare,
Medicaid, and SCHIP Refinement Act of 1999
make a difference during the next year or two?
What is the state of AHCs’ capacity to train and
retain biomedical researchers? What is the difference between M.D.- and Ph.D.-trained investigators? Should some AHCs cultivate clinical investigator “stars” to conduct research?
What is the state of AHCs’ research infrastructure?
How is it funded? What is the ideal, relative to
advancing technology and information systems?
Should certain AHCs serve as “research centers of
excellence”?
Has NIH’s role in supporting biomedical research
changed during the 1990s? Relative to AHCs?
Relative to other organizations?
What impact has reconfiguration of the health
marketplace had on NIH initiatives? What impact
have recommendations made by different NIH
panels had on the various institutes and centers?
What expectations does NIH have of AHCs? How
does it view AHC research relationships?
What types of relationships do private-sector pharmaceutical, biotechnology, and medical-device firms
have with AHCs? With government agencies? With
intermediary organizations, such as CROs?
Is the environment primarily competitive or collaborative relative to the conduct of biomedical research? What forces are driving the private sector?
Should managed care play a greater role in biomedical research? What should its financial contribution
be? How should it contribute (for example, to an allpayer fund, to the health costs of its members in
clinical trials)?
Should there be acknowledged leadership of biomedical research or pluralistic leadership? Who decides?

THE FORUM SESSION
This Forum session will feature four presenters from
various aspects of the health field. John M. Eisenberg,
M.D., M.B.A., administrator of the Agency for Healthcare Research and Quality, DHHS, will provide a stagesetting overview of the continuum of biomedical
research and AHCs’ roles in its perpetuation. Appointed
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to head the Agency for Health Care Policy and Research (its earlier name) in 1997, he previously was
chairman of the Department of Medicine and physicianin-chief at Georgetown University. Prior to that, he was
chief of the Division of General Internal Medicine at
the University of Pennsylvania. A founding commissioner of the Physician Payment Review Commission,
on which he served from 1986 through 1995—chairing
it the last two years—he was the first physician to be
elected president of the Association for Health Services
Research. He also has held numerous other leadership
posts. He is a member of the IOM of the National
Academy of Sciences. Author of more than 250 articles
and book chapters, he received his M.D. degree from
the Washington University School of Medicine and
completed his residency in internal medicine at the
University of Pennsylvania.
Roger E. Meyer, M.D., senior consultant on
clinical research at the AAMC, will review the problems or barriers confronting AHCs and some of the
tensions in the research field. He has served in administrative and policy roles in Washington since 1993, when
he became vice president for medical affairs at George
Washington University. In the mid-1990s, he affiliated
with the Association of Academic Health Centers,
where he completed a study on the impact of managed
care on academic psychiatry. Earlier, he was a fellow at
the Center for Advanced Study in the Behavioral
Sciences at Stanford University, where he helped
organize a study group on the impact of health care
reform on AHCs. From 1977 to 1992, he held various
positions at the University of Connecticut School of
Medicine, first as professor and chair of the Department
of Psychiatry and later as executive dean of the school.
The author of more than 150 papers and six books, he
has led several professional organizations and been a
consultant to numerous federal agencies. He is a
graduate of Harvard Medical School and completed his
residency in psychiatry at Massachusetts Mental Heath
Center in Boston.
Lana R. Skirboll, Ph.D., director of the Office of
Science Policy, NIH, DHHS, will describe NIH’s role
and efforts to address some of the problems and tensions. In her current position, she advises the NIH
director and deputy director and provides leadership to
NIH institutes and centers on science policy issues.
Earlier, she was director of the Office of Science Policy
and Program Planning at the National Institute of
Mental Health, a post she took when the Alcohol Drug
Abuse and Mental Health Administration (ADAMHA)
was reorganized and its three research institutes re-

turned to the NIH. Prior to that she was associate
administrator for science and deputy science advisor at
ADAMHA. A neuroscientist and author of more than
75 scientific publications, she received her Ph.D. degree
in the Department of Pharmacology at Georgetown
University Medical School, and did post-doctoral
training in the Departments of Psychiatry and Pharmacology at the Yale University School of Medicine.
Frank E. Samuel, president of Edison BioTechnology Center, Inc., in Cleveland, will address the privatesector role and pressures. He has headed Edison BioTechnology Center, a consortium of private industry,
research institutions, and the state’s Thomas Edison
Program, since 1989. For the five previous years, he
was the president of the Health Industry Manufacturers
Association (HIMA), the national organization representing health devices, diagnostics, and information
systems manufacturers on state, federal, and international issues. A graduate of Harvard Law School, he
practiced law in Washington, D.C., prior to rejoining
HIMA, where he had worked earlier as vice president
and general counsel. He also served in a variety of
positions at the Department of Health, Education, and
Welfare (the forerunner of DHHS), including deputy
assistant secretary for legislation (health). He is on the
boards of directors of several biotechnology organizations and is a member of the Advisory Committee of
Catalyst Ventures and the Ohio Innovation Fund.
Following brief presentations by each, there will be
a roundtable discussion of the policy implications of
reshaping AHCs’ participation in biomedical research
and the training of research investigators. The key
questions listed earlier will provide a guide for both the
presentations and the discussion.
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